A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
Clinical trial NCT01115556 · COMPLETED
Trial details
- NCT number
- NCT01115556
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-05-01
- Primary completion
- 2012-01-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.